RDIT® Antibody Humanization

The humanized antibody mainly refers to antibody that is re-expressed by a mouse monoclonal antibody via gene cloning and DNA recombination technology. Most of the amino acid sequences are substituted by human sequences, but the affinity and specificity of murine monoclonal antibodies are substantially retained. Simultaneously, the heterologous properties are reduced, which is beneficial to the human body. Recent research has also revealed that antibody humanization should be a powerful tool for the de-immunogenicity of therapeutic antibodies. Creative Biolabs owns a high-level technical team and instruments to provide antibody humanization services to reduce the immunogenicity of your targets of interest.

Introduction of Antibody Humanization

A humanized antibody means that the constant region portion of the antibody (i.e., the CH and CL regions) or the antibody are all encoded by the human antibody gene. Humanized antibodies can greatly reduce the immune side effects of heterologous antibodies on the human body. A wide variety of humanized antibodies, including chimeric antibodies, modified antibodies, surface remodeling of antibodies, as well as fully humanized antibodies have been developed for disease therapy. Meanwhile, pilot studies have indicated that antibody humanization plays an important role in reducing the immunogenicity of potential antibodies in disease treatment.

Antibody engineering for humanization. Fig.1 Antibody engineering for humanization. (Kim, 2005)

RDIT® Antibody Humanization Services

As a professional immunogenicity analysis supplier for therapeutic antibody discovery, Creative Biolabs has developed a novel Rapid De-immunization Technology® (RDIT®) antibody humanization platform to improve the safety and efficacy of candidate antibodies in pre-clinical studies. Currently, we offer a number of antibody humanization services to help the de-immunogenicity of screened targets. Unlike other platforms, the specificity determining residues (SDRs) of the antibody will be engineered into the human framework. In general, the three-dimensional structures, mutation sites of SDRs will be defined by our RDIT® in silico analysis assays. After that, a series of functional assays will be further used to assess the safety, reactivity of the humanized antibody to the patient serum. In addition, we also provide a phage display-based strategy to help the de-immunogenicity of antibodies by using human sequences from phage-displayed antibody libraries. Recent studies conducted by our labs have suggested that RDIT® antibody humanization platform can provide a fast and accurate route for antibody humanization. Basing on our services, the humanized antibody can present a high affinity, specificity, and much fewer immunogenicity properties in the production or long-term treatment process.

Creative Biolabs provides high quality humanized antibody recombination services and technical support to reduce the immunogenicity of the drug. If you are interested in humanized antibody, please contact us for more details.


  1. Kim, S.J.; et al. Antibody Engineering for the Development of Therapeutic Antibodies. Molecules and Cells. 2005, 20(1): 17-29.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.

Online Inquiry

Verification code
Click image to refresh the verification code.


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Germany: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Germany: 44-207-097-1828
Fax: 1-631-207-8356
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us